CatalystFDA/Bio

UPSTREAM BIO STOCK JUMPS 8% ON PHASE 2 SEVERE ASTHMA DATA - SEEKINGALPHA

Phase 2 severe asthma data triggered an 8% stock jump.

What changed

Phase 2 severe asthma data triggered an 8% stock jump.

Why it matters

Phase 2 severe asthma data triggered an 8% stock jump. — impact context not separately stored; see What changed.

Sources